Answers are grounded in this paper and cite their sources.
Influenza viruses and coronaviruses are enveloped, single-stranded RNA viruses that pose persistent and pandemic threats to global public health. Despite belonging to distinct viral families, they share remarkable parallels in modes of transmission, clinical manifestations, and socioeconomic impacts, yet diverge fundamentally in evolutionary mechanisms and epidemiological trajectories. This review compares the history, spread, treatments, and vaccines for these two types of viruses. Influenza viruses possess a segmented genome, which enables antigenic shift and reassortment. In contrast, coronaviruses have large, nonsegmented genomes and rely on recombination, mutation accumulation, and insertions to achieve host switching and immune evasion. Both spread to humans through wildlife (intermediate hosts), live animal markets, intensive agriculture, and global travel. Antiviral strategies have evolved from M2 and neuraminidase inhibitors (NAIs) for influenza to polymerase inhibitors and protease inhibitors for coronavirus, yet drug resistance remains a common challenge. Vaccine platforms, including inactivated, live-attenuated, recombinant, mRNA, and viral vector technologies, have been deployed against both viruses. This review concludes that integrated, platform-based preparedness, encompassing broad-spectrum antivirals, universal vaccines, and proactive ecological surveillance, is essential for building pandemic-resilient public health systems capable of responding to both influenza and coronavirus threats, as well as future emerging respiratory viruses.
No takes yet. Share an insight, caveat, or question.
Zhao et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: